Comprehensive Assessment of PD-L1 and PD-L2 Dysregulation in Gastrointestinal Cancers

References

• Dorrie J . Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy. EMBO Mol. Med.9(2), 135–136 (2017).
   PubMed Web of Science ®Google Scholar
• Zou W , WolchokJD , ChenL. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med.8(328), 328rv324 (2016).
   Web of Science ®Google Scholar
• Ivan P , DominiqueB , NathalieFet al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol.178(5), 2763–2769 (2007).
   PubMed Web of Science ®Google Scholar
• Kuang DM , ZhaoQ , PengCet al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med.206(6), 1327–1337 (2009).
   PubMed Web of Science ®Google Scholar
• Taube JM , AndersRA , YoungGDet al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med.4(127), 127ra137 (2012).
   Web of Science ®Google Scholar
• Topalian SL , DrakeCG , PardollDM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell27(4), 450 (2015).
   PubMed Web of Science ®Google Scholar
• Yearley JH , GibsonC , YuNet al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin. Cancer Res.51(12), 3158–3167 (2017).
   Google Scholar
• Latchman Y , WoodCR , ChernovaTet al. PD-L2 is a second ligand for PD-1 and inhbits T cell activation. Nat. Immunol.2(3), 261–268 (2001).
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ , BoscoA , MillwardMJ , SmallM , NowakAK , LakeRA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat. Rev. Drug Discov.16(4), 264–272 (2017).
   PubMed Web of Science ®Google Scholar
• Torre LA , FreddieB , SiegelRL , JacquesF , JoannieLT , AhmedinJ. Global cancer statistics, 2012. CA Cancer J. Clin.65(2), 87–108 (2015).
   PubMed Web of Science ®Google Scholar
• Edwards BK , ElizabethW , KohlerBAet al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer116(3), 544–573 (2009).
   Web of Science ®Google Scholar
• Center MM , JemalA. International trends in liver cancer incidence rates. Cancer Epidemiol. Biomarkers Prev.20(11), 2362–2368 (2011).
   PubMed Web of Science ®Google Scholar
• Stuart Jon S . Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA310(6), 627–636 (2013).
   PubMed Web of Science ®Google Scholar
• Jamali L , TofighR , TutunchiSet al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J. Cell. Physiol.233(11), 8538–8550 (2018).
   PubMed Web of Science ®Google Scholar
• Hesari A , AzizianM , SheikhiAet al. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: current and future status. Int. J. Cancer144(6), 1215–1226 (2019).
   PubMed Web of Science ®Google Scholar
• Mirzaei R , MirzaeiH , AlikhaniMYet al. Bacterial biofilm in colorectal cancer: what is the real mechanism of action? Microb. Pathog. 142, 104052 (2020).
   PubMed Web of Science ®Google Scholar
• Xu F , LiS , ZhangJet al. Cancer stemness, immune cells, and epithelial-mesenchymal transition cooperatively predict prognosis in colorectal carcinoma. Clin. Colorectal Cancer17(3), e579–e592 (2018).
   PubMed Web of Science ®Google Scholar
• Amin M , LockhartAC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin. Investig. Drugs.24(3), 329–344 (2015).
   PubMed Web of Science ®Google Scholar
• Tagliamonte M , PetrizzoA , MaurielloA , TorneselloML , BuonaguroFM , BuonaguroL. Potentiating cancer vaccine efficacy in liver cancer. Oncoimmunology7(10), e1488564 (2018).
   PubMed Web of Science ®Google Scholar
• Naeli P , PourhanifehMH , KarimzadehMRet al. Circular RNAs and gastrointestinal cancers: epigenetic regulators with a prognostic and therapeutic role. Crit. Rev. Oncol. Hematol.145, 102854 (2020).
   PubMed Web of Science ®Google Scholar
• Iovanna J , MallmannMC , GonçalvesA , TurriniO , DagornJC. Current knowledge on pancreatic cancer. Front. Oncol.2, 6 (2012).
   PubMedGoogle Scholar
• Morrison AH , ByrneKT , VonderheideRH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer4(6), 418–428 (2018).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , TykodiSS , ChowLQet al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.366(26), 2455–2465 (2012).
   PubMed Web of Science ®Google Scholar
• Garon EB , RizviNA , RinaHet al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med.372(21), 2018 (2015).
   PubMed Web of Science ®Google Scholar
• Mann JE , HoesliR , MichmerhuizenNLet al. Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J. Cancer8(3), 332–344 (2017).
   PubMed Web of Science ®Google Scholar
• Mirzaei HR , MirzaeiH , LeeSY , HadjatiJ , TillBG. Prospects for chimeric antigen receptor (CAR) γδ T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett.380(2), 413–423 (2016).
   PubMed Web of Science ®Google Scholar
• Gholamin S , MirzaeiH , RazaviSMet al. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J. Cell. Physiol.233(2), 866–879 (2018).
   PubMed Web of Science ®Google Scholar
• Mirzaei HR , PourghadamyariH , RahmatiMet al. Gene-knocked out chimeric antigen receptor (CAR) T cells: tuning up for the next generation cancer immunotherapy. Cancer Lett.423, 95–104 (2018).
   PubMed Web of Science ®Google Scholar
• Shafabakhsh R , PourhanifehMH , MirzaeiHR , SahebkarA , AsemiZ , MirzaeiH. Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy. Pharmacol. Res.147, 104353 (2019).
   PubMed Web of Science ®Google Scholar
• Vivian J , RaoAA , NothaftFAet al. Toil enables reproducible, open source, big biomedical data analyses. Nat. Biotechnol.35(4), 314–316 (2017).
   PubMed Web of Science ®Google Scholar
• Colaprico A , SilvaTC , OlsenCet al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res.44(8), e71–e71 (2016).
   PubMed Web of Science ®Google Scholar
• Shabalin AA . Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics28(10), 1353–1358 (2012).
   PubMed Web of Science ®Google Scholar
• Messeguer X , EscuderoR , FarreD , NunezO , MartinezJ , AlbaMM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics18(2), 333–334 (2002).
   PubMed Web of Science ®Google Scholar
• Frith M , HansenU , WengZ. Detection of cis-element clusters in higher eukaryotic DNA. Bioinformatics17(10), 878–889 (2001).
   PubMed Web of Science ®Google Scholar
• Wang J , VasaikarS , ShiZ , GreerM , ZhangB. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res.45( W1), W130–W137 (2017).
   PubMed Web of Science ®Google Scholar
• Szklarczyk D , FranceschiniA , WyderSet al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res.43( Database issue), D447–452 (2015).
   PubMed Web of Science ®Google Scholar
• Shannon P , MarkielA , OzierOet al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res.13(11), 2498–2504 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar S , StecherG , TamuraK. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol.33(7), 1870 (2016).
   PubMed Web of Science ®Google Scholar
• Mayakonda A , LinDC , AssenovY , PlassC , KoefflerHP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res.28(11), 1747–1756 (2018).
   PubMed Web of Science ®Google Scholar
• Sheng Q , SamuelsDC , YuH , NessS , ZhaoYY , GuoY. Cancer-specific expression quantitative loci are affected by expression dysregulation. Brief. Bioinform.21(1), 338–347 (2020).
   PubMed Web of Science ®Google Scholar
• Karolchik D , BaertschR , DiekhansMet al. The UCSC genome browser database. Nucleic Acids Res.31(1), 51–54 (2003).
   PubMed Web of Science ®Google Scholar
• Ding L , ChenX , XuXet al. PARP1 suppresses the transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunol. Res.7(1), 136–149 (2019).
   PubMed Web of Science ®Google Scholar
• Shibahara D , TanakaK , IwamaEet al. Intrinsic and extrinsic regulation of PD-L2 expression in oncogene-driven non-small cell lung cancer. J. Thorac. Oncol.13(7), 926–937 (2018).
   PubMed Web of Science ®Google Scholar
• Martínez VG , HidalgoL , ValenciaJet al. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells. Eur. J. Immunol.44(4), 1031–1038 (2014).
   PubMed Web of Science ®Google Scholar
• Baumgart S , EllenriederV , Fernandez-ZapicoME. Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut62(2), 310–316 (2013).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Postow MA , ChesneyJ , PavlickACet al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med.372(21), 2006–2017 (2015).
   PubMed Web of Science ®Google Scholar
• Becht E , GiraldoNA , LacroixLet al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol.17(1), 218 (2016).
   PubMed Web of Science ®Google Scholar
• Bindea G , MlecnikB , HacklHet al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics25(8), 1091–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Szklarczyk D , GableAL , LyonDet al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res.47(D1), D607–D613 (2019).
   PubMed Web of Science ®Google Scholar
• Hazel L , CatherineC , IanC. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat. Rev.41(10), 893–903 (2015).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , DrakeCI , PowderlyJDet al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• George S , Papanicolau-SengosA , LenzoFLet al. PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. OncoImmunology7(12), e1460298 (2018).
   PubMed Web of Science ®Google Scholar
• Ching-Yao Y , Mong-WeiL , Yih-LeongC , Chen-TuW , Pan-ChyrY. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur. J. Cancer50(7), 1361–1369 (2014).
   PubMed Web of Science ®Google Scholar
• Ryosuke H , KenjiK , YuKet al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer116(7), 1757–1766 (2010).
   PubMed Web of Science ®Google Scholar
• Shi SJ , WangLJ , WangGDet al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS ONE8(10), e76012 (2013).
   PubMed Web of Science ®Google Scholar
• Pinto N , ParkJR , MurphyEet al. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. Pediatr. Blood Cancer64(11), e26613 (2017).
   Web of Science ®Google Scholar
• Larsen TV , HussmannD , NielsenAL. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer. Cancer Commun. (Lond)39(1), 30 (2019).
   PubMedGoogle Scholar
• Moratin J , MetzgerK , SafaltinAet al. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck41(8), 2484–2491 (2019).
   PubMed Web of Science ®Google Scholar
• Nakano T , TakizawaK , UezatoA , TaguchiK , TohS , MasudaM. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncology90, 30–37 (2019).
   PubMed Web of Science ®Google Scholar
• Baruah P , BullenkampJ , WilsonPOG , LeeM , KaskiJC , DumitriuIE. TLR9 mediated tumor-stroma interactions in human papilloma virus (HPV)-positive head and neck squamous cell carcinoma up-regulate PD-L1 and PD-L2. Front. Immunol.10, 1644–1644 (2019).
   PubMed Web of Science ®Google Scholar
• Arrieta O , Montes-ServínE , Hernandez-MartinezJ-Met al. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget8(60), 101994–102005 (2017).
   PubMedGoogle Scholar
• Kollmann D , IgnatovaD , JedamzikJet al. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology7(6), e1435226 (2018).
   PubMed Web of Science ®Google Scholar
• Derks S , NasonKS , LiaoXet al. Epithelial PD-L2 expression marks barrett’s esophagus and esophageal adenocarcinoma. Cancer Immunol. Res.3(10), 1123–1129 (2015).
   PubMed Web of Science ®Google Scholar
• Baptista MZ , SarianLO , DerchainSF , PintoGA , VassalloJ. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum. Pathol.47(1), 78–84 (2016).
   PubMed Web of Science ®Google Scholar
• Takada K , ToyokawaG , KinoshitaFet al. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. J. Cancer Res. Clin. Oncol.146(10), 2639–2650 (2020).
   PubMed Web of Science ®Google Scholar
• Furuse M , KuwabaraH , IkedaNet al. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer20(1), 277 (2020).
   PubMed Web of Science ®Google Scholar
• Mataki N , KikuchiK , KawaiTet al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am. J. Gastroenterol.102(2), 302–312 (2007).
   PubMed Web of Science ®Google Scholar
• Jung HI , JeongD , JiSet al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. Treat.49(1), 246–254 (2017).
   PubMed Web of Science ®Google Scholar
• Zou J , ZhuangM , YuXet al. MYC inhibition increases PD-L1 expression induced by IFN-gamma in hepatocellular carcinoma cells. Mol. Immunol.101, 203–209 (2018).
   PubMed Web of Science ®Google Scholar
• Peng C , HuQ , YangF , ZhangH , LiF , HuangC. BCL6-mediated silencing of PD-1 ligands in germinal center B cells maintains follicular T cell population. J. Immunol.202(3), 704–713 (2019).
   PubMed Web of Science ®Google Scholar
• Martínez VG , LauraH , JarisVet al. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells. Eur. J. Immunol.44(4), 1031–1038 (2014).
   PubMed Web of Science ®Google Scholar
• Tao LH , ZhouXR , LiFCet al. A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunol. Immunother.66(3), 309–318 (2017).
   PubMed Web of Science ®Google Scholar
• Zou J , WuD , LiT , WangX , LiuY , TanS. Association of PD-L1 gene rs4143815 C >G polymorphism and human cancer susceptibility: a systematic review and meta-analysis. Pathol. Res. Pract.215(2), 229–234 (2019).
   PubMed Web of Science ®Google Scholar
• Schonfeld M , ZhaoJ , KomatzA , WeinmanSA , TikhanovichI. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J. Biol. Chem.295(20), 7126–7137 (2020).
   PubMed Web of Science ®Google Scholar
• Kim MY , KohJ , KimS , GoH , JeonYK , ChungDH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer88(1), 24–33 (2015).
   PubMed Web of Science ®Google Scholar
• Madore J , VilainRE , MenziesAMet al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res.28(3), 245–253 (2015).
   PubMed Web of Science ®Google Scholar
• Wang Z . TMIC-01. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology5(11), e1196310 (2016).
   PubMed Web of Science ®Google Scholar
• Wang H , YaoH , LiCet al. PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation. Oncoimmunology6(7), e1327494 (2017).
   PubMed Web of Science ®Google Scholar
• Miller A , AsmannY , CattaneoLet al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J.7(9), e612 (2017).
   PubMedGoogle Scholar
• Sabari JK , LeonardiGC , ShuCAet al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann. Oncol.29(10), 2085–2091 (2018).
   PubMed Web of Science ®Google Scholar
• Yarchoan M , AlbackerLA , HopkinsACet al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight4(6), e126908 (2019).
   PubMed Web of Science ®Google Scholar
• Thompson ED , ZahurakM , MurphyAet al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut66(5), 794–801 (2017).
   PubMed Web of Science ®Google Scholar
• Koirala P , RothME , GillJet al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci. Rep.6, 30093 (2016).
   PubMed Web of Science ®Google Scholar
• Kitano A , OnoM , YoshidaMet al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open2(2), e000150 (2017).
   PubMed Web of Science ®Google Scholar
• Kitamura T , QianBZ , SoongDet al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med.212(7), 1043–1059 (2015).
   PubMed Web of Science ®Google Scholar
• Oshima H , HiokiK , PopivanovaBKet al. Prostaglandin E(2) signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology140(2), 596–607.e597 (2011).
   PubMed Web of Science ®Google Scholar
• Lahmar Q , KeirsseJ , LaouiD , MovahediK , Van OvermeireE , Van GinderachterJA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim. Biophys. Acta1865(1), 23–34 (2016).
   PubMed Web of Science ®Google Scholar
• Cai X , ZhangL , WeiW. Regulatory B cells in inflammatory diseases and tumor. Int. Immunopharmacol.67, 281–286 (2019).
   PubMed Web of Science ®Google Scholar
• Hayakawa K , FormicaAM , ColomboMJet al. B cells generated by B-1 development can progress to chronic lymphocytic leukemia. Ann. NY Acad. Sci.1362, 250–255 (2015).
   PubMed Web of Science ®Google Scholar
• Wilke CM , WuK , ZhaoE , WangG , ZouW. Prognostic significance of regulatory T cells in tumor. Int. J. Cancer127(4), 748–758 (2010).
   PubMed Web of Science ®Google Scholar
• Teng MW , NgiowSF , RibasA , SmythMJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res.75(11), 2139–2145 (2015).
   PubMed Web of Science ®Google Scholar
• Ock CY , KeamB , KimSet al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin. Cancer Res.22(9), 2261–2270 (2016).
   PubMed Web of Science ®Google Scholar
• Dong L , LvH , LiWet al. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget7(22), 33350–33362 (2016).
   PubMedGoogle Scholar
• Clark CA , GuptaHB , SareddyGet al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res.76(23), 6964–6974 (2016).
   PubMed Web of Science ®Google Scholar
• Zhao L , LiC , LiuFet al. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco. Targets Ther.10, 2115–2126 (2017).
   PubMed Web of Science ®Google Scholar
• Lastwika KJ , WilsonW , LiQK3rdet al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res.76(2), 227–238 (2016).
   PubMed Web of Science ®Google Scholar
• Moore EC , CashHA , CarusoAMet al. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol. Res.4(7), 611–620 (2016).
   PubMed Web of Science ®Google Scholar
• Okita R , MaedaA , ShimizuK , NojimaY , SaishoS , NakataM. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol. Immunother.66(7), 865–876 (2017).
   PubMed Web of Science ®Google Scholar
• Suh KJ , SungJH , KimJWet al. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget8(38), 63901–63910 (2017).
   PubMedGoogle Scholar
• Oki E , OkanoS , SaekiHet al. Protein expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma. Oncology93(6), 387–394 (2017).
   PubMed Web of Science ®Google Scholar
• Dinkel BA , KremerKN , RollinsMR , MedlynMJ , HedinKE. GRK2 mediates TCR-induced transactivation of CXCR4 and TCR-CXCR4 complex formation which drives PI3Kγ/PREX1 signaling and T cell cytokine secretion. J. Bio. Chem.293(36), 14022–14039 (2018).
   PubMed Web of Science ®Google Scholar
• Guo Y , WangLP , LiCet al. Effects of Ginsenoside Rb1 on expressions of phosphorylation Akt/phosphorylation mTOR/phosphorylation PTEN in artificial abnormal hippocampal microenvironment in rats. Neurochem. Res.43(10), 1927–1937 (2018).
   PubMed Web of Science ®Google Scholar
• Shahenda EN , YongqingL , DeanDC. Mutation of the Rb1 pathway leads to overexpression of mTor, constitutive phosphorylation of Akt on serine 473, resistance to anoikis, and a block in c-Raf activation. Mol. Cell. Biol.29(21), 5710–5717 (2009).
   PubMed Web of Science ®Google Scholar